Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

Another jury in the same courthouse handed a verdict last month to a separate Zantac manufacturer, GlaxoSmithKline. On May 23, an Illinois jury sided with both drug manufacturers in the first ...

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...

GSK welcomed a decision from the Delaware Supreme Court to review a lower court ruling that allowed the introduction of expert evidence in the ongoing litigation over Zantac, or ranitidine.

Twelve days after GSK secured a key win in Florida, with a state court tossing expert testimony on the cancer-causing potential of heartburn drug Zantac (ranitidine), the British company has ...

Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drug makers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused ...

(Reuters) – The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer ...

GSK emphasised that the scientific consensus, supported by 16 epidemiological studies involving over a million patients, did not establish a reliable link between ranitidine and cancer.

By Brendan Pierson (Reuters) -The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree ...